Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Recent Data on Non-BCMA Targeting Bispecifics in R/R MM
Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.
Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM
The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.
Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.
The Development of Bispecifics-Based Combination Therapies in MM
Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.
Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.
Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.
Treatment with Teclistamab Following Progression on CAR-T in R/R MM
The panel shares their experiences with the sequencing of BCMA-targeting therapies in MM, with particular focus on treatment of patients who progress on CAR T-cell therapy with teclistamab.
Bispecific Antibodies in Development for the Treatment of R/R MM
Dr Jack Khouri highlights recent data updates on other BCMA-targeting bispecific antibodies that are in clinical development in multiple myeloma.
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.
Selecting Patients with MM for Teclistamab and Optimal Sequencing
The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.
Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.
2 Clarke Drive Cranbury, NJ 08512